On April 22nd, Yang Xia, Chairman of Jinbo Biotechnology (920982. BJ), a leading enterprise in the restructuring of collagen, and Jin Xing, founder of New Oxygen (SY. US), appeared on stage together and announced a strategic cooperation. The new product, Weiyimei ColPact, under Jinbo Biotechnology, will be exclusively used by the medical beauty chain under New Oxygen. The latter's New Oxygen Youth Clinic will launch a "miracle collagen" anti-aging solution covering the face and scalp based on this product.

Two years ago, the two sides openly debated the price of Weiyimei (an injection grade humanized collagen product with anti-aging effects). In 2024, Jinbo Biotechnology issued a public statement, directly targeting the disruption of market pricing caused by new oxygen. At that time, some medical beauty institutions on the New Oxygen platform offered Weiyimei at a price as low as 1513 yuan per unit, while Jinbo Biology provided a reference average price of 6800 yuan per unit.

On the day of announcing the cooperation, Yang Xia responded for the first time to the shift from confrontation to handshake with New Oxygen: firstly, the situation of Jinbo Biology has changed, and secondly, her judgment on New Oxygen has changed.

As the first biomaterial in China to use recombinant humanized collagen, Weiyimei had limited production capacity when it was first launched, and the product had not yet received market feedback. Yang Xia said that the initial price of Weiyimei was 6900 yuan per unit because the production capacity was only 300 liters. Before the treatment volume reached 100000 units, Yang Xia was worried about adverse reactions from users every day, let alone expanding production capacity.

Until the shipment volume of Weiyimei reached 250000 units and there were no adverse reactions, Yang Xia decided to expand production capacity. However, during the process of expanding production capacity from 300 liters to 3 tons, Jinbo Biotechnology encountered technological challenges and production capacity remained unstable. If product prices were lowered at that time, the production capacity gap would be even greater. Yang Xia said that the hope for the company's survival at that time was that the products could not be reduced in price.

As of now, Weiyimei has been on the market for over 5 years, and Jinbo Biotechnology has achieved a production capacity breakthrough of 3 tons, and will continue to expand to 5 tons in the future. At this stage, Yang Xia agreed to the pricing plan of "one unit costs 1999 yuan, and two units cost 2999 yuan" for the new oxygen.

As a leading domestic enterprise in the upstream of recombinant collagen, Jinbo Biotechnology has continued to make significant efforts to expand its production capacity in recent years, with a cumulative investment of over 1.7 billion yuan in production capacity. In addition to investing in heavy assets such as building industrial parks, establishing production bases, and winning industrial land, Jinbo Biotechnology will also complete a targeted issuance of 2 billion yuan to raise funds by 2025, and increase capital for its Beijing subsidiary with 165 million yuan of its own funds, all aimed at the landing of production capacity projects and upgrading production capacity scale.

Another reason for the shift in the relationship with new oxygen is that Yang Xia's judgment of new oxygen has improved. At the end of 2025, Venus and Yang Xia will meet for the first time. After a meal, Venus found that Yang Xia was a pure scientist, and Yang Xia also found that Venus was not the "Internet businessman who only knows how to fight price wars".

After breaking the ice, Venus sent a team of more than 20 people to the headquarters of Jinbo Biology in Shanxi. This group of people was described by Yang Xia as' turning Jinbo upside down '. They asked about the distribution of atoms and questioned the stability of the triple helix structure of recombinant collagen, and Jinbo Biology provided answers one by one. Later, Jinxing sent a message to Yang Xia saying that his team had become a fan of Yang Xia's circle.

The "triple helix structure" is the basic structural unit of collagen. In the field of recombinant collagen, only with this correct spatial folding structure can collagen be recognized by cells and exert its biological functions. In addition, having a stable triple helix structure means that the product does not require the addition of crosslinking agents, thereby avoiding the potential toxicity and embolization risks of chemical substances.

As of April 2026, 18 Class III medical device collagen registration certificates have been issued domestically. Yang Xia is not worried about the intense competition in the market. These newly added registration certificates do not clearly indicate the "triple helix structure". Weiyimei is still the only product with a 100% humanized sequence and a complete triple helix. She believes that the precision of the structure of recombinant collagen will become a key competitive factor in the future, which will determine whether the product can achieve long-term, high-frequency repeated injections for medical aesthetics.

Regarding why Jinbo Biology chose New Oxygen, Yang Xia replied to the Economic Observer, "New Oxygen gave me accurate data. In the past 5 years, Jinbo Biotechnology has completed 4 million clinical injections of recombinant humanized collagen, and Yang Xia has never received accurate data from other customers. "These data can improve the product, even the treatment and injection methods. No matter how many injections are used, New Oxygen can provide me with feedback data, allowing me to accurately know where consumers are dissatisfied. These dissatisfactions are the starting point of my innovation.

In this cooperation between manufacturers and channels, Jinbo Biotechnology provided core materials and technology, while New Oxygen was delivered through its 56 stores in 17 cities across the country in a standardized manner, avoiding the cost markup of traditional medical beauty distribution layers.

At present, Jinbo Biotechnology has three "equipment certificates" for recombinant collagen. The first one is used for its own brand Weiyimei's recombinant humanized collagen freeze-dried fiber, the second one is used for the "Platinum Research" collagen needle in cooperation with L'Oreal Group's brand Xiuliko, and the third one is the Weiyimei ColPact exclusively for the New Oxygen Youth Clinic.

In the past six months, Juzi Biotechnology and Chuangjian Medical have successively been approved for the "Mechanical Three Certificates" of recombinant collagen, breaking the monopoly position maintained by Jinbo Biotechnology since 2021. Next, several companies including Jinbo Biotechnology are still in the process of applying for multiple recombinant collagen "three certificates", covering multiple medical fields such as gynecology, urology, and orthopedics.